Pharma
Biocon Ltd
BIOCON · NSE · INE376G01013Monday, 26 Oct 2026Vol: 26.3L traded · 54.4% delivered11:46 am
Market Cap₹53,358 Cr
P/E96.4
P/B1.6
EPS₹3.38
Div Yield0.2%
ROE1.3%
ROCE0.9%
ROE1.3%
1Y Return-5.47%
Avg. Volume2.4M
Delivery %54.37%
Price Chart
52-Week Range
About
Biocon Ltd is a Pharma company listed on NSE.
Technicals
Free account
Register freeTechnicals
Create a free account to view momentum, moving averages, and delivery signals.
Quant
Premium
UpgradeQuant metrics
Upgrade to view volatility, drawdown, factor, and risk metrics.
Key Ratios
Market Cap₹53,358 Cr
Current Price₹325.8
52W High / Low₹447.15 / ₹318.4
Stock P/E96.4
Price to Book1.6
EPS (TTM)₹3.38
Dividend Yield0.2%
ROE1.3%
1Y Return-5.47%
Day Change+0.71%
Profit & Loss
| Period | TTM | FY26 | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | ₹17,321 Cr | ₹16,927 Cr | ₹15,262 Cr | ||||||||||
| Expenses | ₹13,785 Cr | ₹13,456 Cr | ₹12,008 Cr | ||||||||||
| Operating Profit | ₹3,536 Cr | ₹3,471 Cr | ₹3,254 Cr | ||||||||||
| OPM % | 20.0% | 21.0% | 21.0% | ||||||||||
| Other Income | ₹-82 Cr | ₹-76 Cr | ₹1,217 Cr | ||||||||||
| Depreciation | ₹2,049 Cr | ₹1,957 Cr | ₹1,687 Cr | ||||||||||
| Interest | ₹927 Cr | ₹990 Cr | ₹897 Cr | ||||||||||
| Profit Before Tax | ₹479 Cr | ₹448 Cr | ₹1,887 Cr | ||||||||||
| Tax | ₹63 Cr | ₹79 Cr | ₹458 Cr | ||||||||||
| Net Profit | ₹416 Cr | ₹369 Cr | ₹1,429 Cr | ||||||||||
| EPS (₹) | 3.4 | 2.4 | 8.4 | ||||||||||
| Dividend Payout % | — | 21% | 6% |
Financial history locked
Register freeRegister free to see 10 more years.
Quarterly Results
| Quarter | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | ₹4,336 Cr | ₹4,517 Cr | ₹4,173 Cr | ₹4,296 Cr | |||||||||
| Expenses | ₹3,489 Cr | ₹3,496 Cr | ₹3,340 Cr | ₹3,460 Cr | |||||||||
| Operating Profit | ₹847 Cr | ₹1,020 Cr | ₹834 Cr | ₹835 Cr | |||||||||
| OPM % | 20.0% | 23.0% | 20.0% | 19.0% | |||||||||
| Depreciation | ₹547 Cr | ₹513 Cr | ₹515 Cr | ₹473 Cr | |||||||||
| Interest | ₹213 Cr | ₹232 Cr | ₹210 Cr | ₹272 Cr | |||||||||
| Net Profit | ₹137 Cr | ₹199 Cr | ₹-52 Cr | ₹133 Cr | |||||||||
| EPS (₹) | 0.9 | 0.8 | 1.1 | 0.6 |
Quarterly history locked
Register freeRegister free to see 9 more quarters.
Balance Sheet
| Period | FY26 | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Liabilities | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Equity Capital | ₹810 Cr | ₹600 Cr | ₹600 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Reserves | ₹33,221 Cr | ₹21,044 Cr | ₹19,183 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Borrowings | ₹15,434 Cr | ₹18,362 Cr | ₹16,277 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Other Liabilities | ₹13,944 Cr | ₹18,534 Cr | ₹19,693 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Total Liabilities | ₹63,409 Cr | ₹58,540 Cr | ₹55,753 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Assets | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Fixed Assets | ₹36,486 Cr | ₹31,963 Cr | ₹30,644 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Investments | ₹1,779 Cr | ₹1,127 Cr | ₹1,000 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Receivables | — | — | — | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Inventory | — | — | — | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Cash & Equivalents | — | — | — | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Other Assets | ₹18,157 Cr | ₹16,941 Cr | ₹16,117 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Total Assets | ₹63,409 Cr | ₹58,540 Cr | ₹55,753 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Balance sheet history locked
Register freeRegister free to see 10 more years.
Cash Flow
| Period | Operating | Investing | Financing | Net Cash Flow |
|---|---|---|---|---|
| FY26 | ₹1,994 Cr | ₹-1,883 Cr | ₹-924 Cr | ₹-812 Cr |
| FY25 | ₹4,061 Cr | ₹-203 Cr | ₹-1,854 Cr | ₹2,004 Cr |
| FY24 | ₹2,954 Cr | ₹-1,002 Cr | ₹-2,333 Cr | ₹-380 Cr |
| FY23 | ||||
| FY22 | ||||
| FY21 | ||||
| FY20 | ||||
| FY19 | ||||
| FY18 | ||||
| FY17 | ||||
| FY16 | ||||
| FY15 |
Cash flow history locked
Register freeRegister free to see 10 more years.
Peer Comparison
| Company | M.Cap | P/E | ROE | 1Y Return |
|---|---|---|---|---|
| 3B BlackBio Dx Ltd | ₹1,210 Cr | 21.4 | +20.2% | +17.9% |
| Aarey Drugs & Pharmaceuticals Ltd | — | — | +2.75% | +59.84% |
| Aarti Drugs Ltd | ₹3,429 Cr | 18.0 | +13.37% | +11.57% |
| Aarti Pharmalabs Ltd | ₹7,495 Cr | 35.2 | +8.51% | +14.26% |
| Abbott India Ltd | — | — | +34.46% | -7.16% |
Mutual Fund Holdings
Free account
Register freeMutual fund holdings
Create a free account to see institutional ownership snapshots.
Bulk & Block Deals
Free account
Register freeBulk & block deals
Create a free account to view recent institutional deal activity.
Analyst Estimates
Free account
Register freeAnalyst estimates
Create a free account to view analyst estimate summaries.
Latest News
2026-09-21Announcement under Regulation 30 (LODR)-Press Release / Media ReleaseBSE Filing2026-08-06Biocon Ltd (BOM:532523) (Q1 2027) Earnings Call Highlights: Biosimilars Surge 16% as Net Profit ...GuruFocus.com2026-08-03Biocon Announces U.S. Commercial Launch of Yesafili™, a Biosimilar to Regeneron’s Eylea® 2 mgBusiness Wire
Documents & Filings
rupiya.io is for research and education only. Metrics shown are not investment advice. Validate with SEBI-regulated disclosures before acting.